Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 mass balance and pharmacokinetics study of [14C]BAY 3283142 in healthy male volunteers
NL-OMON56921Phase 1Completed
- Sponsor
- Bayer
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BAY3283142 in chronic kidney disease (CKD), sponsored by Bayer. Primary endpoints: %AE,ur(0-tlast) and %AE,fec(0-tlast) of BAY 3283142 and metabolites, AUC of total radioactivity in plasma and whole blood and 1 more. Started Oct 2024; status: completed.
02
Drugs
BAY3283142
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NL-OMON56921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56921.